An active pharmaceutical ingredient is used in a finished pharmaceutical product (FPP), intended to carry certain pharmacological actions or otherwise have a direct effect in the diagnosis, cure, treatment, mitigation or prevention of various diseases, or in some cases in restoring, correcting or modifying human physiological functions. Sales of pharmaceutical ingredient are on the rise due to a substantial increase in high-potency API (HPAPI) and peptide API manufacturing.<\/p>\n
A new study conducted by Persistence Market Research reveals that the US$ 151.9 Bnglobalactive pharmaceutical ingredient market<\/strong>will grow toUS$ 158.3 Bn by 2017 end<\/strong>, reflecting a Y-o-Y growth rate of 4.2%. This market is estimated to further increase toUS$ 225.2 Bn<\/strong>, expanding at aCAGR of 4.5%<\/strong>over the forecast period (2016 – 2025)<\/p>\n Get Sample Copy of Report @https:\/\/www.persistencemarketresearch.com\/samples\/11260<\/a><\/strong><\/p>\n Company Profiles<\/strong><\/p>\n Get To Know Methodology of Report @https:\/\/www.persistencemarketresearch.com\/methodology\/11260<\/a><\/strong><\/p>\n PMR in its report, titled “Active Pharmaceutical Ingredient Market – Global Industry Analysis and Forecast, 2016 – 2025” has cited some of the key factors prompting the global sales of API, which include:<\/p>\n Access Full Report @https:\/\/www.persistencemarketresearch.com\/checkout\/11260<\/a><\/strong><\/p>\n According to the report, small molecule API type segment holds promising investment opportunities for market participants on account of the numerous off-patent events incurred in the last five years coupled with a strong penetration of small scale manufacturers in Asia.<\/p>\n On the basis region, APAC’s API market was valued atUS$ 61.4 Bn in 2016<\/strong>and is projected to witness the highestCAGR of 5.1 %<\/strong>during the forecast period to reach a valuation ofUS$ 95.6 Bn<\/strong>.<\/p>\n This is primarily owing to the leadership of China and India in SMEs as well as their strong distribution network in overseas markets especially in US, South Africa, and Europe.<\/p>\n Asian pharmaceuticals CMOs are competing on the basis of cost and timeline for API manufacturing and are attracting U.S.-based pharmaceuticals companies that are willing to outsource manufacturing requirements.<\/p>\n Meanwhile, Europe is projected to be the second fastest growing market for API and is expected to reach US$ 42.5 Bn by 2025-end. Manufacturers in Europe are prioritizing high-quality standards, advanced manufacturing installations, and high purity of intermediates (API).<\/p>\n<\/div>\n Explore Extensive Coverage of PMR`sLife Sciences & Transformational Health<\/a>Landscape<\/strong><\/p>\n Molecular Diagnostics Market –<\/strong><\/p>\n Molecular Diagnostics Market<\/a>Segmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.<\/p>\n Next-Generation Sequencing Market –<\/strong><\/p>\n Next Generation Sequencing Market<\/a>Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.<\/p>\n Ophthalmology devises Market –<\/strong><\/p>\n Ophthalmology devises Market<\/a>Segmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.<\/p>\n Intravenous Iron Drugs Market –<\/strong><\/p>\n Intravenous (IV) Iron Drugs Market<\/a>Segmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A\/S, Rockwell Medical Technologies, Inc., and Sanofi.<\/p>\n Syndromes Progressive Ataxia Weakness Disorders Market –<\/strong><\/p>\n Treatments forSyndromes of Progressive Ataxia and Weakness Disorders Market<\/a>Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.<\/p>\n About us:<\/strong><\/p>\n Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.<\/p>\n To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.<\/p>\n Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.<\/p>\n Contact us:<\/strong><\/p>\n 305 Broadway, 7th Floor <\/p>\n Tags: Active Pharmaceutical Ingredient Market Demand<\/a>, Active Pharmaceutical Ingredient Market Development<\/a>, Active Pharmaceutical Ingredient Market Revenue Share<\/a>, Active Pharmaceutical Ingredient Market Supply<\/a>, Active Pharmaceutical Ingredient Market Analysis<\/a>, Active Pharmaceutical Ingredient market forecast<\/a>, Active Pharmaceutical Ingredient Market Growth<\/a>, Active Pharmaceutical Ingredient Market Size<\/a>, Active Pharmaceutical Ingredient Market Trends<\/a><\/p>\n 305 Broadway, 7th Floor Tags:<\/b> 305 Broadway, 7th Floor![\"active](\"http:\/\/www.persistencemarketresearch.com\/images\/active-pharmaceutical-ingredients-market.jpg\" "\\"")
<\/p>\n\n
\n
\n
\n
\n
\nNew York City, NY 10007
\nUnited States
\nPh.no. +1-646-568-7751
\nE-mail id-sales@persistencemarketresearch.com<\/a>
\nWebsite:https:\/\/www.persistencemarketresearch.com<\/a><\/p>\n<\/div>\n
Contact Information:<\/b><\/p>\n
New York City, NY 10007
United States
Ph.no.<\/strong> +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com<\/a><\/strong>
Website: https:\/\/www.persistencemarketresearch.com<\/a><\/strong><\/p>\n
<\/a>, Extended Distribution<\/a>, Research Newswire<\/a>, English<\/a><\/p>\n<\/div>\n
Contact Information:<\/h3>\n
New York City, NY 10007
United States
Ph.no.<\/strong> +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com<\/a><\/strong>
Website: https:\/\/www.persistencemarketresearch.com<\/a><\/strong><\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/05\/4027-1588608710.png\")
An active pharmaceutical ingredient is used in a finished pharmaceutical product (FPP), intended to carry certain pharmacological actions or otherwise have a direct effect in the diagnosis, cure, treatment, mitigation or prevention of various diseases, or in some cases in restoring, correcting or modifying human physiological functions. Sales of pharmaceutical ingredient are on the rise … Continue reading Explore Active Pharmaceutical Ingredient Market Set To Reach US$ 225.2 Bn In Revenues By 2025<\/span><\/a> Continue Reading